FDA Approves Talimogene Laherparepvec to Treat Metastatic Melanoma



The FDA has approved the first oncolytic virus therapy, talimogene laherparepvec (T-VEC). The drug was approved for the treatment of metastatic melanoma that cannot be removed surgically.



Source link

Comments are closed.